Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Shares Issued: 2020-2024

Historic Shares Issued for SAB Biotherapeutics (SABS) over the last 2 years, with Dec 2024 value amounting to -$3.

  • SAB Biotherapeutics' Shares Issued fell 100.00% to -$3 in Q4 2024 from the same period last year, while for Dec 2024 it was $59.7 million, marking a year-over-year decrease of 11.28%. This contributed to the annual value of $20,409 for FY2024, which is 99.97% down from last year.
  • According to the latest figures from Q4 2024, SAB Biotherapeutics' Shares Issued is -$3, which was down 100.01% from $20,412 recorded in Q1 2024.
  • In the past 5 years, SAB Biotherapeutics' Shares Issued registered a high of $59.6 million during Q4 2023, and its lowest value of -$4.2 million during Q4 2021.
  • Its 3-year average for Shares Issued is $7.5 million, with a median of $7,830 in 2022.
  • In the last 5 years, SAB Biotherapeutics' Shares Issued tumbled by 16,761.00% in 2021 and then soared by 242,900.00% in 2023.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' Shares Issued stood at $25,000 in 2020, then plummeted by 16,761.00% to -$4.2 million in 2021, then surged by 282.55% to $7.6 million in 2022, then spiked by 684.47% to $59.6 million in 2023, then plummeted by 100.00% to -$3 in 2024.
  • Its last three reported values are -$3 in Q4 2024, $20,412 for Q1 2024, and $59.6 million during Q4 2023.